Logo image of EDIT

EDITAS MEDICINE INC (EDIT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EDIT - US28106W1036 - Common Stock

2.04 USD
+0.05 (+2.51%)
Last: 1/6/2026, 12:18:57 PM
Fundamental Rating

1

EDIT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of EDIT have multiple concerns. EDIT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EDIT had negative earnings in the past year.
EDIT had a negative operating cash flow in the past year.
EDIT had negative earnings in each of the past 5 years.
EDIT had a negative operating cash flow in each of the past 5 years.
EDIT Yearly Net Income VS EBIT VS OCF VS FCFEDIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -99.05%, EDIT is doing worse than 73.96% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1485.43%, EDIT is doing worse than 80.00% of the companies in the same industry.
Industry RankSector Rank
ROA -99.05%
ROE -1485.43%
ROIC N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
EDIT Yearly ROA, ROE, ROICEDIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EDIT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDIT Yearly Profit, Operating, Gross MarginsEDIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

2

2. Health

2.1 Basic Checks

EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EDIT has more shares outstanding
EDIT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, EDIT has a worse debt to assets ratio.
EDIT Yearly Shares OutstandingEDIT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EDIT Yearly Total Debt VS Total AssetsEDIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

EDIT has an Altman-Z score of -11.69. This is a bad value and indicates that EDIT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.69, EDIT is doing worse than 74.91% of the companies in the same industry.
A Debt/Equity ratio of 4.02 is on the high side and indicates that EDIT has dependencies on debt financing.
EDIT's Debt to Equity ratio of 4.02 is on the low side compared to the rest of the industry. EDIT is outperformed by 79.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 4.02
Debt/FCF N/A
Altman-Z -11.69
ROIC/WACCN/A
WACC8.45%
EDIT Yearly LT Debt VS Equity VS FCFEDIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.86, EDIT is doing worse than 65.85% of the companies in the same industry.
A Quick Ratio of 2.86 indicates that EDIT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.86, EDIT is doing worse than 63.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
EDIT Yearly Current Assets VS Current LiabilitesEDIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

2

3. Growth

3.1 Past

EDIT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.03%.
The Revenue for EDIT has decreased by -24.90% in the past year. This is quite bad
Measured over the past years, EDIT shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%

3.2 Future

The Earnings Per Share is expected to grow by 10.34% on average over the next years. This is quite good.
EDIT is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -16.97% yearly.
EPS Next Y28.52%
EPS Next 2Y27.04%
EPS Next 3Y18.37%
EPS Next 5Y10.34%
Revenue Next Year-41.77%
Revenue Next 2Y-37.6%
Revenue Next 3Y-28.35%
Revenue Next 5Y-16.97%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EDIT Yearly Revenue VS EstimatesEDIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M
EDIT Yearly EPS VS EstimatesEDIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
Also next year EDIT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDIT Price Earnings VS Forward Price EarningsEDIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDIT Per share dataEDIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

EDIT's earnings are expected to grow with 18.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.04%
EPS Next 3Y18.37%

More info and screens

0

5. Dividend

5.1 Amount

EDIT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EDITAS MEDICINE INC

NASDAQ:EDIT (1/6/2026, 12:18:57 PM)

2.04

+0.05 (+2.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-03 2026-03-03/amc
Inst Owners47.29%
Inst Owner Change0%
Ins Owners0.19%
Ins Owner Change-0.14%
Market Cap199.14M
Revenue(TTM)46.38M
Net Income(TTM)-199.84M
Analysts73.33
Price Target5.04 (147.06%)
Short Float %11.46%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-28.23%
Min EPS beat(2)-63.79%
Max EPS beat(2)7.33%
EPS beat(4)1
Avg EPS beat(4)-40.18%
Min EPS beat(4)-63.79%
Max EPS beat(4)7.33%
EPS beat(8)3
Avg EPS beat(8)-15.9%
EPS beat(12)6
Avg EPS beat(12)-7.53%
EPS beat(16)10
Avg EPS beat(16)-3.06%
Revenue beat(2)2
Avg Revenue beat(2)78.71%
Min Revenue beat(2)47.32%
Max Revenue beat(2)110.1%
Revenue beat(4)3
Avg Revenue beat(4)174.34%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)546.84%
Revenue beat(8)4
Avg Revenue beat(8)133.14%
Revenue beat(12)7
Avg Revenue beat(12)116.99%
Revenue beat(16)10
Avg Revenue beat(16)100.47%
PT rev (1m)25%
PT rev (3m)23.44%
EPS NQ rev (1m)2.98%
EPS NQ rev (3m)-5.84%
EPS NY rev (1m)0%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)22.97%
Revenue NQ rev (3m)24.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)15.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.29
P/FCF N/A
P/OCF N/A
P/B 14.8
P/tB 14.8
EV/EBITDA N/A
EPS(TTM)-2.38
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.48
BVpS0.14
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.05%
ROE -1485.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 4.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.57%
Cap/Sales 2.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -11.69
F-Score2
WACC8.45%
ROIC/WACCN/A
Cap/Depr(3y)98.25%
Cap/Depr(5y)126.71%
Cap/Sales(3y)18.09%
Cap/Sales(5y)18.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
EPS Next Y28.52%
EPS Next 2Y27.04%
EPS Next 3Y18.37%
EPS Next 5Y10.34%
Revenue 1Y (TTM)-24.9%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%12265.57%
Revenue Next Year-41.77%
Revenue Next 2Y-37.6%
Revenue Next 3Y-28.35%
Revenue Next 5Y-16.97%
EBIT growth 1Y47.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.79%
EBIT Next 3Y15.21%
EBIT Next 5YN/A
FCF growth 1Y-15.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.01%
OCF growth 3YN/A
OCF growth 5YN/A

EDITAS MEDICINE INC / EDIT FAQ

Can you provide the ChartMill fundamental rating for EDITAS MEDICINE INC?

ChartMill assigns a fundamental rating of 1 / 10 to EDIT.


What is the valuation status for EDIT stock?

ChartMill assigns a valuation rating of 0 / 10 to EDITAS MEDICINE INC (EDIT). This can be considered as Overvalued.


How profitable is EDITAS MEDICINE INC (EDIT) stock?

EDITAS MEDICINE INC (EDIT) has a profitability rating of 0 / 10.


How financially healthy is EDITAS MEDICINE INC?

The financial health rating of EDITAS MEDICINE INC (EDIT) is 2 / 10.